AUTO4作为一种新型TRBC1靶向CAR T细胞疗法，在LibraT1研究中展示出了一定的安全性与疗效，尤其是在高剂量组中，部分患者获得了持久的完全缓解。

The MTD was determined to be duvelisib 25 mg BID plus 20 mg ruxolitinib BID. Baseline histologies included 14 (29%) TFH lymphomas, 13 (27%) PTCL-not otherwise specified, 7 (14%) mycosis fungoides (MF) ...

The Competition Commission of Pakistan (CCP) is currently finalising the PTCL and Telenor merger, which is possibly one of the most complicated cases of the country’s corporate sector history ...

Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data ...